Inari Medical, Inc. (NASDAQ:NARI) Shares Purchased by Motley Fool Asset Management LLC

Motley Fool Asset Management LLC increased its position in shares of Inari Medical, Inc. (NASDAQ:NARI) by 8.3% during the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 44,239 shares of the company’s stock after acquiring an additional 3,381 shares during the period. Motley Fool Asset Management LLC owned about 0.08% of Inari Medical worth $2,872,000 at the end of the most recent quarter.

Other hedge funds have also recently bought and sold shares of the company. Knights of Columbus Asset Advisors LLC lifted its stake in Inari Medical by 99.7% during the 4th quarter. Knights of Columbus Asset Advisors LLC now owns 45,621 shares of the company’s stock worth $2,962,000 after acquiring an additional 22,780 shares in the last quarter. Bamco Inc. NY raised its position in Inari Medical by 18.2% in the 3rd quarter. Bamco Inc. NY now owns 557,937 shares of the company’s stock valued at $36,489,000 after purchasing an additional 86,000 shares in the last quarter. Canada Pension Plan Investment Board acquired a new stake in Inari Medical in the 3rd quarter valued at about $2,564,000. Fiera Capital Corp raised its position in Inari Medical by 63.4% in the 3rd quarter. Fiera Capital Corp now owns 560,756 shares of the company’s stock valued at $36,673,000 after purchasing an additional 217,606 shares in the last quarter. Finally, Asset Management One Co. Ltd. raised its position in Inari Medical by 19.5% in the 3rd quarter. Asset Management One Co. Ltd. now owns 47,390 shares of the company’s stock valued at $3,099,000 after purchasing an additional 7,720 shares in the last quarter. Institutional investors and hedge funds own 90.98% of the company’s stock.

Insider Buying and Selling

In related news, Director William Hoffman sold 1,451 shares of the firm’s stock in a transaction that occurred on Tuesday, April 16th. The stock was sold at an average price of $40.00, for a total transaction of $58,040.00. Following the transaction, the director now owns 999,782 shares in the company, valued at approximately $39,991,280. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. In related news, Director William Hoffman sold 1,451 shares of the firm’s stock in a transaction that occurred on Tuesday, April 16th. The stock was sold at an average price of $40.00, for a total transaction of $58,040.00. Following the transaction, the director now owns 999,782 shares in the company, valued at approximately $39,991,280. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, CFO Mitch C. Hill sold 6,000 shares of the firm’s stock in a transaction that occurred on Friday, April 12th. The stock was sold at an average price of $40.96, for a total value of $245,760.00. Following the transaction, the chief financial officer now owns 181,294 shares in the company, valued at approximately $7,425,802.24. The disclosure for this sale can be found here. Insiders have sold 47,451 shares of company stock worth $1,949,000 in the last quarter. 10.60% of the stock is owned by insiders.

Analysts Set New Price Targets

A number of equities research analysts have issued reports on the company. Canaccord Genuity Group reaffirmed a “buy” rating and issued a $75.00 price target on shares of Inari Medical in a research report on Friday, April 12th. Needham & Company LLC reaffirmed a “buy” rating and issued a $72.00 price target on shares of Inari Medical in a research report on Wednesday, March 6th. Piper Sandler lowered Inari Medical from an “overweight” rating to a “neutral” rating and reduced their price target for the company from $85.00 to $55.00 in a research report on Thursday, February 29th. Finally, Truist Financial reduced their price target on Inari Medical from $61.00 to $52.00 and set a “hold” rating on the stock in a research report on Friday, March 22nd. Two investment analysts have rated the stock with a hold rating and four have issued a buy rating to the company. According to MarketBeat.com, Inari Medical has a consensus rating of “Moderate Buy” and an average price target of $73.71.

Inari Medical Price Performance

Shares of NARI traded up $0.35 during mid-day trading on Friday, reaching $38.42. The company’s stock had a trading volume of 1,115,180 shares, compared to its average volume of 1,131,658. Inari Medical, Inc. has a 12-month low of $36.73 and a 12-month high of $71.85. The stock has a market cap of $2.23 billion, a PE ratio of -1,280.67 and a beta of 0.84. The company’s 50 day moving average is $45.26 and its 200 day moving average is $54.54.

Inari Medical (NASDAQ:NARI) last released its quarterly earnings data on Wednesday, February 28th. The company reported ($0.08) EPS for the quarter, missing analysts’ consensus estimates of $0.01 by ($0.09). Inari Medical had a negative net margin of 0.33% and a positive return on equity of 1.23%. The business had revenue of $132.10 million during the quarter, compared to analysts’ expectations of $131.82 million. During the same quarter in the previous year, the company posted ($0.11) EPS. The company’s revenue was up 22.5% compared to the same quarter last year. As a group, sell-side analysts anticipate that Inari Medical, Inc. will post -0.39 EPS for the current fiscal year.

Inari Medical Profile

Inari Medical, Inc builds minimally invasive, novel, and catheter-based mechanical thrombectomy devices and accessories for the specific disease states in the United States. The company provides ClotTriever system, which is designed to core, capture, and remove large clots from large vessels for treatment of deep vein thrombosis and peripheral thrombus; FlowTriever system, a large bore catheter-based aspiration and mechanical thrombectomy system to remove large clots from large vessels in the peripheral vasculature for treating pulmonary embolism and other complex venous thromboembolism cases; InThrill system to treat small vessel thrombosis; and LimFlow system for patients who have chronic limb-threatening ischemia with no suitable endovascular or surgical revascularization options and risk of major amputation.